Core Insights - The core mission of the company is to leverage mRNA medicine to create significant impacts on public health, focusing on collaboration with stakeholders [1] Seasonal Vaccine Franchise - The company has established a seasonal vaccine franchise aimed at high-risk populations, with three approved products currently [2] - Positive Phase III results have been achieved for flu and flu plus COVID vaccines, while the Norovirus vaccine is in the Phase III enrollment stage [2] Oncology and Rare Disease Therapeutics - The company plans to utilize cash generated from the seasonal vaccine franchise to invest in oncology and rare disease therapeutics [1] - A significant year for oncology is anticipated in 2026, with numerous data releases expected [2]